Deal of the Day — limited-time pharmacy picks!
Inlybest-1

Inlybest-1

Salt Composition: Axitinib

Expiry Date: 01/2028

Special offer

Buy at $8.18

$8.18

Inclusive of all taxes

▼

2 x14

About The Product

Kidney Cancer

Inlybest 1mg Tablet is used for the treatment of kidney cancer. Inlybest 1mg tablet contains Axitinib as an active substance, and it is indicated for the treatment of renal cell carcinoma (a type of cancer that begins in the kidney). This anticancer formulation belongs to a group of medications known as tyrosine kinase inhibitors. Inlybest 1mg tablet is available in tablet form and works by blocking the action of an abnormal protein.

Uses

Kidney cancer

Side Effects

Mild or major side effects may occur during treatment with Inlybest 1mg tablets. If side effects last longer than usual, inform your general practitioner as soon as possible.

  • ​Stomach pain
  • Heartburn 
  • Headache 
  • Dizziness 
  • Rash 
  • Itching 
  • Dry skin
  • Pale skin
  • Fast heartbeat
  • Hair loss
  • Ringing in the ears
  • Thirst 
  • Hemorrhoids 
  • A wound or cut that will not heal
  • Diarrhea 

How To Use

  • ​Take the Inlybest 1mg tablet as prescribed by your health professional.
  • Ensure you take this cancer-fighting formulation in the same amount as directed by your physician.
  • In case of an overdose, the patient is advised to consult a general practitioner as soon as possible if any unusual symptoms occur.
  • Inlybest 1mg tablet should be swallowed as a whole.
  • Let your doctor know if you have liver, thyroid, kidney disease, etc, or are on some other medications.
  • Inlybest tablet is not recommended for pregnant and breastfeeding women.

How It Works

Inlybest 1mg tablet helps prevent the progression of cancer by inhibiting angiogenesis and blocking tumor growth. It selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.

The formulation is mainly eliminated in the feces (about 41%) with nearly 12% of the original dose as unchanged axitinib. There is also 23% eliminated in the urine, most of which are metabolites.

Safety Advice

Alcohol
It is advisable not to consume alcohol while taking the Inlybest 1mg tablet.
Pregnancy
Do not take the Inlybest 1mg tablet without consulting the doctor, in case of pregnancy. Inlybest 1mg tablet is considered not safe to use in case of pregnancy as it may harm the developing baby, according to research evidence.
Breast Feeding
Without a doctor's consultation, do not take this medicine if you're breastfeeding. Inlybest 1mg tablet may cause toxicity to the developing baby as it may be transferred through the milk of the mother, so it's not considered safe to use Inlybest 1mg tablet during breastfeeding.
Driving
It is advisable not to drive or operate heavy machinery, as one of the side effects of the medicine. Inlybest 1mg tablet can make you feel sleepy, affect your vision, and reduce alertness. It is advised not to drive if these symptoms exist while taking the Inlybest 1mg tablet.
Kidney
Do not take the Inlybest tablet without a doctor's consultation in case of kidney problems. Patients with severe kidney disease should use Inlybest 1mg tablet with caution, and the patient may require an adjustment in dose as recommended by the doctor. A Regular kidney test should be done to monitor the side effects of Inlybest 1mg tablet on the kidneys.
Liver
Share your medical history with the doctor in case of liver disease before taking this medicine. Patients with severe liver disease should use Inlybest 1mg tablet with caution, and the patient may require an adjustment in dose as recommended by the doctor. A Regular liver test should be done to monitor the side effects of Inlybest 1mg tablet on the kidneys.

Missed Doses

  • ​ If you miss a scheduled dose of Inlybest-1 tablet, contact your medical practitioner immediately to know the ways of coping with the missed or skipped dose.
  • ​

FAQs

​ Inlybest-1 contains Axitinib as an active substance and it is indicated for the treatment of renal cell carcinoma (a type of cancer that begins in the kidney).

It helps in decreasing the spread of cancerous cells. ​

Reference

  1. Gross-Goupil M, François L, Quivy A, Ravaud A. (2023). Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 29(7):269-77 - https://pubmed.ncbi.nlm.nih.gov/24250243/
  2. Keating GM. (2023). Axitinib: a review in advanced renal cell carcinoma. Drugs. 75(16):1903-13 - https://pubmed.ncbi.nlm.nih.gov/26487541/
  3. Mi-Hyang Jung, Yun-Seok Choi, Sang-Wook Yi, Sang Joon An, Jee-Jeon Yi, Sang-Hyun Ihm, So-Young Lee, Jong-Chan Youn, Woo-Baek Chung, Hae Ok Jung, Ho-Joong Youn. (2025). Socioeconomic status and cardiovascular mortality in over 170,000 cancer survivors, European Heart Journal - Quality of Care and Clinical Outcomes, 11(4), 406–414 - https://pubmed.ncbi.nlm.nih.gov/38964851/
  4. Oldani M, Cantone MC, Gaudenzi G, Carra S, Dicitore A, Saronni D, Borghi MO, Lombardi A, Caraglia M, Persani L, Vitale G. (2024). Exploring the multifaceted antitumor activity of axitinib in lung carcinoids. Front Endocrinol (Lausanne) - https://pubmed.ncbi.nlm.nih.gov/39050569/
  5. Shin SJ, Lee JL, Kwon TG, Shim BY, Chung HS, Kim SH, Park SH.(2025). Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy. Cancer Res Treat. 55(2):643-651 - https://pubmed.ncbi.nlm.nih.gov/36470258/
  6. Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Slot KB, Damkier P, Hofland K, Borregaard J, Ersbøll J, Salmonson T, Pieters R, Sylvester R, Mickisch G, Bergh J, Pignatti F. (2024). The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. ;20(2):196-201.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026